CN102665684A - 用于吸入的组合物 - Google Patents

用于吸入的组合物 Download PDF

Info

Publication number
CN102665684A
CN102665684A CN2010800478259A CN201080047825A CN102665684A CN 102665684 A CN102665684 A CN 102665684A CN 2010800478259 A CN2010800478259 A CN 2010800478259A CN 201080047825 A CN201080047825 A CN 201080047825A CN 102665684 A CN102665684 A CN 102665684A
Authority
CN
China
Prior art keywords
calcium
composition
zinc
salt
metal ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800478259A
Other languages
English (en)
Chinese (zh)
Inventor
格伦·马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovata Ltd
Original Assignee
Innovata Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovata Ltd filed Critical Innovata Ltd
Publication of CN102665684A publication Critical patent/CN102665684A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800478259A 2009-10-21 2010-10-21 用于吸入的组合物 Pending CN102665684A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0918450.8 2009-10-21
GBGB0918450.8A GB0918450D0 (en) 2009-10-21 2009-10-21 Composition
PCT/GB2010/001955 WO2011048379A2 (en) 2009-10-21 2010-10-21 Composition

Publications (1)

Publication Number Publication Date
CN102665684A true CN102665684A (zh) 2012-09-12

Family

ID=41426476

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800478259A Pending CN102665684A (zh) 2009-10-21 2010-10-21 用于吸入的组合物

Country Status (7)

Country Link
US (1) US20130004542A1 (enExample)
EP (1) EP2490670B1 (enExample)
JP (1) JP2013508344A (enExample)
CN (1) CN102665684A (enExample)
CA (1) CA2777899C (enExample)
GB (1) GB0918450D0 (enExample)
WO (1) WO2011048379A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113163843A (zh) * 2018-11-01 2021-07-23 尼科创业贸易有限公司 凝胶和结晶粉末
CN115046816A (zh) * 2022-03-11 2022-09-13 桂林优利特医疗电子有限公司 一种尿液有形成分分析仪用结晶质控物的制备方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
CA2809666C (en) 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
ES2710537T3 (es) 2010-09-29 2019-04-25 Pulmatrix Operating Co Inc Polvos secos catiónicos
US20150165038A1 (en) * 2012-02-10 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and sorbitol
CA2865972C (en) * 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
US20150174064A1 (en) * 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US20150150802A1 (en) * 2012-07-05 2015-06-04 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhaler compositions comprising long acting muscarinic antagonists
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
EP2939251A2 (en) * 2012-12-27 2015-11-04 3M Innovative Properties Company Electrochemical device and method of making the same
EA201591218A1 (ru) * 2012-12-27 2015-11-30 Майкродоуз Терапьютикс, Инк. Способы и композиции для введения оксибутинина
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
JP2015116367A (ja) * 2013-12-19 2015-06-25 重人 下山 寝具装置、寝具装置制御方法及びプログラム
CN103830194A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗固体分散体及含有其的药物组合物
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
WO2017100656A1 (en) * 2015-12-11 2017-06-15 Otitopic Inc. Dry powder formulations of aspirin for inhalation
WO2019139479A1 (en) * 2018-01-11 2019-07-18 Rob Janssen Compositions and methods for the treatment of lung emphysema and other forms of copd
KR20240130716A (ko) * 2021-12-16 2024-08-29 알베올러스 바이오, 인코포레이티드 질환의 치료를 위한 분무 건조된 흡입가능한 생물치료제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016205A2 (en) * 1996-10-17 1998-04-23 Inhale Therapeutic Systems Stable glassy state powder formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8802174D0 (en) * 1988-02-01 1988-03-02 Quadrant Bioresources Ltd Method of drying macromolecules
WO1990011756A1 (en) 1989-04-12 1990-10-18 Aberdeen University Slow release vitreous systems
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
EP0563455A1 (en) 1992-03-31 1993-10-06 Purac Biochem B.V. Particulate solid products containing a lump forming inhibitor
CA2115065C (en) * 1992-06-12 2000-10-03 Kiyoyuki Sakon Ultrafine particle powder for inhalation and method for production thereof
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
JP3095624B2 (ja) 1994-07-19 2000-10-10 株式会社ボッシュオートモーティブシステム 積層型熱交換器の偏平チューブのろう付け方法
CA2197982C (en) 1994-08-04 2010-03-23 Bruce Joseph Roser Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
GB9423419D0 (en) 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
DE69628007T2 (de) 1995-06-07 2003-11-27 Elan Drug Delivery Ltd., Ruddington Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
GB9621825D0 (en) 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
EP1071465A1 (en) 1998-03-18 2001-01-31 Ronai, Peter Amorphous glasses for stabilising sensitive products
RU2221552C2 (ru) 1998-11-13 2004-01-20 Джаго Рисерч Аг Сухой порошок для ингаляции
WO2000053157A1 (en) 1999-03-05 2000-09-14 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
UA75375C2 (en) 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10050995A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10050994A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10141376A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
DE10141377A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
JP2003062074A (ja) * 2001-08-29 2003-03-04 Tomohiko Hashiba 吸入装置
DE10203749A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203753A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203741A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1480996A1 (en) * 2002-02-04 2004-12-01 Glaxo Group Limited Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
AU2003218308B2 (en) 2002-03-20 2006-07-20 Advanced Inhalation Research, Inc. hGH (human growth hormone) formulations for pulmonary administration
WO2004060343A1 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
JP2005060330A (ja) * 2003-08-18 2005-03-10 Tomohiko Hashiba 球状タンパク質粉体とその製造方法
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
RU2577698C2 (ru) * 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
KR20120015295A (ko) * 2009-03-26 2012-02-21 풀매트릭스 인코퍼레이티드 점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016205A2 (en) * 1996-10-17 1998-04-23 Inhale Therapeutic Systems Stable glassy state powder formulations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113163843A (zh) * 2018-11-01 2021-07-23 尼科创业贸易有限公司 凝胶和结晶粉末
CN115046816A (zh) * 2022-03-11 2022-09-13 桂林优利特医疗电子有限公司 一种尿液有形成分分析仪用结晶质控物的制备方法

Also Published As

Publication number Publication date
WO2011048379A3 (en) 2012-01-05
WO2011048379A2 (en) 2011-04-28
GB0918450D0 (en) 2009-12-09
JP2013508344A (ja) 2013-03-07
US20130004542A1 (en) 2013-01-03
EP2490670A2 (en) 2012-08-29
CA2777899C (en) 2016-03-29
EP2490670B1 (en) 2019-04-17
CA2777899A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CN102665684A (zh) 用于吸入的组合物
CN1150895C (zh) 用于吸入给药的干粉
ES3033142T3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
RS65494B1 (sr) Kombinacije antagonista muskarinskog receptora i agonista beta-2-adrenoreceptora
TW201204412A (en) Dry powder formulation comprising an antimuscarinic drug
JP2015519394A (ja) キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法
US20040062719A1 (en) Particulate inhalation carrier
KR102330428B1 (ko) 흡입 제형용 건조 분말 및 이의 제조방법
CN105338967A (zh) 包含布地奈德和福莫特罗的药物组合物
EP2821062A1 (en) Novel dry powder inhaler formulations
CN111481550A (zh) 含有噻托溴铵和阿福特罗的药物制剂
KR102696616B1 (ko) 흡입 제형용 건조 분말 및 이의 제조방법
KR102898819B1 (ko) 흡입용 건조 분말 제제를 위한 신규 담체 입자
RU2823554C1 (ru) Новые частицы носителя для сухих порошковых составов для ингаляции
RU2795231C2 (ru) Новые частицы носителя для сухих порошковых составов для ингаляции
CN112469443A (zh) 用于吸入用干粉制剂的新型载体颗粒
HK40037203A (en) Novel carrier particles for dry powder formulations for inhalation
HK1239571A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
TW201618759A (zh) 具有經改善之組合型活性成分之穩定性的吸入型調配物乾粉末
HK1182002A (en) Dry powder formulation comprising a phosphodiesterase inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20160203

C20 Patent right or utility model deemed to be abandoned or is abandoned